681853-95-2

Usage

Uses

Used in Pharmaceutical Chemistry:
(-)-1-[(4S,5S)-2,2-dimethyl-5-vinyl-1,3-dioxolan-4-yl]-2-(tert-butyldiphenylsilyloxy)ethan-1-one serves as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique structure and functional groups allow for the development of new drugs with specific therapeutic properties.
Used in Materials Chemistry:
In the field of materials chemistry, (-)-1-[(4S,5S)-2,2-dimethyl-5-vinyl-1,3-dioxolan-4-yl]-2-(tert-butyldiphenylsilyloxy)ethan-1-one is utilized for the creation of advanced materials with tailored properties. Its versatility in organic synthesis enables the production of materials with applications in various industries, such as electronics, coatings, and adhesives.
Used in Organic Synthesis:
As an intermediate in organic synthesis, (-)-1-[(4S,5S)-2,2-dimethyl-5-vinyl-1,3-dioxolan-4-yl]-2-(tert-butyldiphenylsilyloxy)ethan-1-one is employed in the preparation of complex organic molecules. Its presence in the synthesis process allows for the creation of compounds with specific functionalities and properties, which can be further utilized in various applications across different industries.

Upstream product

• 50-69-1 D-ribose 
• 58479-61-1 tert-butylchlorodiphenylsilane 
• 96690-02-7 5-O-(tert-butyldiphenylsilyl)-2,3-O-isopropylidene-D-ribofuranose 
• 10257-32-6 D-ribose 
• 67814-68-0 2,3-O-isopropylidene-D-ribofuranose 
• 681853-93-0 (1R)-(-)-1-[(4R,5S)-2,2-dimethyl-5-vinyl-1,3-dioxolan-4-yl]-2-(tert-butyldiphenylsilyloxy)ethan-1-ol 
• 532-20-7 D-Ribose 

Downstream Products

• 952418-10-9 (1R)-(+)-1-[(4S,5S)-2,2-dimethyl-5-vinyl-1,3-dioxolan-4-yl]-1-[(tert-butyldiphenylsilyloxy)methyl]-2-propen-1-ol 
• 952418-11-0 (1R,4R,5S)-9-[3-(tert-butyldiphenylsilyloxymethyl)-4,5-isopropylidenedioxy-2-cyclopenten-1-yl]-N⁶,N⁶-bis(tert-butoxycarbonyl)adenine 
• 952418-12-1 (1R,4R,5S)-9-[3-(tert-butyldiphenylsilyloxymethyl)-4,5-isopropylidenedioxy-2-cyclopenten-1-yl]adenine 
• 72877-50-0 neplanocin A 
• 303963-92-0 (3aR,6aR)-6-(((tert-butyldiphenylsilyl)oxy)methyl)-2,2-dimethyl-3a,6a-dihydro-4H-cyclopenta[d][1,3]dioxol-4-one 
• 681853-92-9 (1R,4S,5S)-(+)-4,5-isopropylidenedioxy-1-(tert-butyldiphenylsilyloxymethyl)-2-cyclopenten-1-ol 
• 491577-97-0 (3aR,4R,6aR)-(6-benzyloxymethyl-5-fluoro-2,2-dimethyl-4,6a-dihydro-3aH-cyclopenta[1,3]dioxol-4-yloxy)-tert-butyl-diphenyl-silane 
• 865838-26-2 RX-3117 
• 1067238-45-2 (3R,4S,5S)-3-(benzyloxymethyl)-1,6-dien-4,5-(O-isopropylidenedioxy)-heptan-3-ol 
• 491578-01-9 ((3aR,4R,6aR)-6-(benzyloxymethyl)-5-iodo-2,2-dimethyl-4,6a-dihydro-3aH-cyclopenta[d][1,3]dioxol-4-yloxy)(tert-butyl)diphenylsilane 
• 681853-99-6 (1R,4S,5S)-1-(benzyloxymethyl)-2-en-4,5-(O-isopropylidenedioxy)-cyclopentan-1-ol 
• 1440510-02-0 C₃₀H₃₃ClN₄O₃Si 
• 915694-38-1 (3aR,3bR,4aS,5S,5aS)-3b-(((tert-butyldiphenylsilyl)oxy)methyl)-2,2-dimethylhexahydrocyclopropa[3,4]cyclopenta[1,2-d][1,3]dioxol-5-ol 
• 1440510-01-9 C₂₅H₃₂O₄Si 

Relevant academic research and scientific papers

POLYMORPHIC COMPOUNDS AND USES THEREOF

The present invention provides compounds and methods of use thereof for treatment of certain disorders and conditions, for example brain injuries such as stroke or traumatic brain injuries.

COMPOUNDS AND METHODS FOR TREATING ADDICTION AND RELATED DISORDERS

The present invention relates to compounds and methods of use thereof for treatment of certain disorders and conditions, for example an addiction or compulsive disorder.

Compounds and methods for treating neurological and cardiovascular conditions

The present invention relates to compounds and methods of use thereof for treatment of certain disorders and conditions, for example brain injuries such as stroke or traumatic brain injuries.

NON-RIBOSE CONTAINING INHIBITORS OF HISTONE METHYLTRANSFERASE DOT1L FOR CANCER TREATMENT

A compound of Formula I, a pharmaceutically acceptable salt thereof, a prodrug thereof, or combinations thereof: wherein R1 is H, methyl, or benzyl: R2 is 2-cyanoethyl, 2-methoxycarbonylethyl, or 2-iodoethyl; X is N or S; wherein if

Synthesis, activity and metabolic stability of non-ribose containing inhibitors of histone methyltransferase DOT1L

Histone methyltransferase DOT1L is a drug target for MLL leukemia. We report an efficient synthesis of a cyclopentane-containing compound that potently and selectively inhibits DOT1L (Ki = 1.1 nM) as well as H3K79 methylation (IC50 ～

Fluorocyclopentenyl-cytosine with broad spectrum and potent antitumor activity

On the basis of the potent biological activity of cyclopentenyl- pyrimidines, fluorocyclopentenyl-pyrimidines were designed and synthesized from d-ribose. Among these, the cytosine derivative 5a showed highly potent antigrowth effects in a broad range of

Total syntheses of a conformationally locked North-type methanocarba puromycin analogue and a dinucleotide derivative

An original synthetic approach for the first synthesis of an enantiopure methanocarba puromycin (3'-α-aminoacylamino-3'-deoxyadenosine) analogue and its cytidine dinucleotide derivative is described. Each compound is conformationally locked in a North-typ

Synthesis of (-)-neplanocin A with the highest overall yield via an efficient Mitsunobu coupling

Neplanocin A was synthesized in very high isolated yield and purity, in 10 steps from d-ribose via an efficient Mitsunobu coupling using N6-bis-Boc-protected adenine. In fact, this synthesis is a short pathway to enantiopure neplanocin A giving

Stereoselective synthesis of 3-hydroxymethyl-D-cyclopentenone, the versatile intermediate for the synthesis of carbocyclic nucleosides

The preparative and stereoselective synthesis (45-50% overall yields, >50 g scale) of the key carbasugars 7a-d was achieved from D-ribose via stereoselective Grignard reaction and oxidative rearrangement as key reactions. Copyright Taylor & Francis, Inc.

Preparative and Stereoselective Synthesis of the Versatile Intermediate for Carbocyclic Nucleosides: Effects of the Bulky Protecting Groups to Enforce Facial Selectivity

The preparative and stereoselective synthesis (45-50% overall yields) of the target compound 17 has been accomplished from D-ribose. The bulky protecting groups such as TBDPS and Trityl enforced the facial selectivity during Grignard reaction to give the